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Introduction: In this study, we aimed to examine the association between paracetamol administration in the
intensive care unit (ICU) and mortality in critically ill patients.
Methods: We conducted a multicenter retrospective observational study in four ICUs. We obtained information
on paracetamol use, body temperature, demographic, clinical and outcome data from each hospital’s clinical
information system and admissions and discharges database. We performed statistical analysis to assess the
association between paracetamol administration and hospital mortality.
Results: We studied 15,818 patients with 691,348 temperature measurements at 4 ICUs. Of these patients, 10,046
(64%) received at least 1 g of paracetamol. Patients who received paracetamol had lower in-hospital mortality
(10% vs. 20%, P <0.001), and survivors were more likely to have received paracetamol (66% vs. 46%; P <0.001).
However, patients treated with paracetamol were also more likely to be admitted to the ICU after surgery (70% vs. 51%;
P <0.001) and/or after elective surgery (55% vs. 37%; P <0.001). In multivariate logistic regression analysis including a
propensity score for paracetamol treatment, we found a significant and independent association between the use of
paracetamol and reduced in-hospital mortality (adjusted odds ratio =0.60 (95% confidence interval (CI), 0.53 to 0.68),
P <0.001). Cox proportional hazards analysis showed that patients who received paracetamol also had a significantly
longer time to death (adjusted hazard ratio =0.51 (95% CI, 0.46 to 0.56), P <0.001). The association between
paracetamol and decreased mortality and/or time to death was broadly consistent across surgical and medical
patients. It remained present after adjusting for paracetamol administration as a time-dependent variable. However,
when such time-dependent analysis was performed, the association of paracetamol with outcome lost statistical
significance in the presence of fever and suspected infection and in patients in the lower tertiles of Acute Physiology
and Chronic Health Evaluation II scores.
Conclusions: Paracetamol administration is common in the ICU and appears to be independently associated with
reduced in-hospital mortality and time to death after adjustment for multiple potential confounders and propensity
score. This association, however, was modified by the presence of fever, suspected infection and lesser illness severity
and may represent the effect of indication bias.* Correspondence: rinaldo.bellomo@austin.org.au
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Paracetamol, the acetaminophen prodrug, is a widely
used analgesic and antipyretic drug in the intensive
care unit (ICU) [1]. However, no randomized con-
trolled trials have been performed to assess its use as
an antipyretic in this setting in developed countries,
and only limited studies of its effects or associations
with outcome in critically ill patients overall have
been conducted [2,3]. This lack of data is of potential
concern because paracetamol may carry some risks.
For example, it can act as a liver toxin by depleting
its intracellular glutathione concentration through the
effects of one of its metabolites, called N-acetyl-p-
benzoquinone imine [4]. This effect is exacerbated by
fasting, a condition commonly seen in ICU patients.
Moreover, the toxic dose of paracetamol is highly
variable. For example, after administration of a standard
dose of 4 g/day for 2 to 3 weeks, an increase in alanine
aminotransferase to about three times the normal value is
common [5]. Thus, it is conceivable that when used in
critically ill patients who have other risk factors for liver
injury and/or are in a fasting state, paracetamol may lead
to subclinical adverse effects that contribute to morbidity
and mortality.
In addition, paracetamol is also likely to affect the
febrile response to critical illness. Fever is common in
critically ill patients [6,7] and may be deleterious,
especially in ICU patients, by increasing metabolic
rate, heart rate, cardiac work and catecholamine pro-
duction [8-10]. Thus, by lowering metabolic demand,
the antipyretic effect of paracetamol may have a pro-
tective effect. However, in the presence of infection,
fever may be protective [11,12]. Thus, the potential
balance between the beneficial and detrimental effects
of paracetamol on body temperature may depend on
the cause of fever [13-15]. Moreover, there remains
substantial clinical uncertainty about the effect of pharma-
cologic antipyretic therapy on outcomes in critically ill
patients in general [15].
Thus, paracetamol prescription is common [6,14]
and may have important consequences. Despite such
potential risks and/or benefits, little is known about
the epidemiology and safety of paracetamol adminis-
tration in the ICU. Observational studies are therefore
desirable as a first step toward improved understand-
ing and knowledge of paracetamol administration.
Accordingly, we aimed to investigate the epidemiology
and associations of paracetamol in a cohort of critically
ill patients. In particular, we hypothesized that para-
cetamol administration might be common, associated
with no overall differences in mortality in critically ill
patients, but associated with increased risk of death
in febrile patients with infection as the admission
diagnosis.Materials and methods
Study design
This study was a multicenter retrospective observational
study conducted at the ICUs of Princess Alexandra
Hospital (Brisbane), Royal Prince Alfred Hospital (Sydney),
St George Hospital (Sydney) and St Vincent’s Hospital
(Melbourne). These ICUs are all tertiary units in major
metropolitan centers in Australia.
Ethical approval
The data collection and data analysis were approved by the
Austin Hospital Ethics Committee (approval H2010/04086)
and by ethics committees in each of the participating
hospitals (see Acknowledgements for details). As this
study was deemed to be low risk, the need for informed
consent was waived.
Patients
We studied all adult patients admitted to the study
ICUs during the period when electronic data capture
of paracetamol and body temperature prescription
was possible (from 6 January 2000 to 1 September 2010 in
hospital A, from 1 January 2009 to 31 December 2010 in
hospital B, from 1 July 2009 to 9 June 2011 in hospital C
and from 1 July 2009 to 31 December 2012 in hospital D).
We excluded readmission episodes and patients for whom
data were not available for temperature, admission diag-
nosis or vital status at hospital discharge and patients with
insufficient data for illness severity assessment.
We additionally extracted the following variables from
the relevant unit databases: demographics, physiological
parameters over the first 24 hours in the ICU, admission
source, Acute Physiology and Chronic Health Evaluation
(APACHE) II score, Simplified Acute Physiology Score II,
body temperature during ICU stay (recorded by any route)
and vital status at ICU and hospital discharge.
Body temperature measurements
For all patients, all ICU temperature values (total of
691,348) during the entire ICU admissions were available.
Measurement methods included tympanic, axillary, per
rectum, esophageal and bladder temperature probes. Fever
was defined as a body temperature >38.0°C [16-18].
Statistical analyses
All analysis was performed using SAS version 9.4
software (SAS Institute, Cary, NC, USA) and STATA
version 11.0 software (StataCorp, College Station, TX,
USA). Continuous data are presented as mean (standard
deviation) or medians (interquartile range) depending on
the underlying distribution of the data. Categorical data
are reported as proportions (n).
The primary outcome measure for this study was
in-hospital mortality, and the secondary outcome was
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one dose either intravenously or via nasogastric tube or
per rectum or orally) were first compared with those not
exposed to paracetamol by means of univariate analysis,
and time to event was assessed by log-rank test. The
results are presented as Kaplan-Meier survival plots.
Multivariate analysis for in-hospital mortality using
logistic regression and Cox proportional hazards regres-
sion were then conducted, and the results are expressed
as odds ratios (ORs) or hazard ratios (HRs), respect-
ively. Proportionality assumptions were determined
both visually and by fitting interactions with the log
of survival time.
Given the retrospective nature of the study design, to
account for imbalance between patients who received
paracetamol compared with those who did not, each
patient’s propensity to receive paracetamol was included
as a covariate in multivariate analysis. The propensity to
receive paracetamol for each patient was determined by
using a multivariable logistic regression with “paracetamol
administration” or “no paracetamol administration” as the
outcome. This model was constructed using both stepwise
and backward selection procedures (with an inclusion
P-value of 0.05) before a final assessment for clinical
and biological plausibility. Variables included in the final
propensity score model are displayed in Additional file 1:
Table E1. This propensity score was used as a covariate in
the multivariate models in conjunction with APACHE II
score, hospital, surgical patient, infection as admission
diagnosis, presence of fever, APACHE III admission
diagnostic group as modified by the Australian and
New Zealand Intensive Care Society Adult Patient
Database [16], treatment limitation and paracetamol
administration. Additional propensity score matching
analysis was also performed by matching “paracetamol
administration” with “no paracetamol administration,”
with each patient matched to within ±5% of the pro-
pensity score.
In addition, to account for the competing risk of
patients’ dying before having the opportunity to receive
paracetamol, time to death was analyzed using Cox pro-
portional hazards regression with paracetamol exposure
(yes vs. no) treated as a time-dependent variable. However,
as fever was not found to be time-dependent, it was not
treated as such in the analysis.
For sensitivity analysis, the same analyses were performed
in the following subgroups:
1. Surgical (post-operative) patients
2. Medical (non-operative) patients
3. Patients with and without fever (any temperature
above and below 38°C, respectively)
4. Patients with and without fever (any temperature
above and below 38.3C, respectively)5. Patients with and without fever (any temperature
above and below 38.5°C, respectively)
6. Patients with and without fever (any temperature
above and below 39°C, respectively)
7. Patients with hypothermia (any temperature <35°C)
8. Medical patients with fever (any temperature >38°C)
who had infection as admission diagnosis
9. Patients with and without cirrhosis
10. Patients who received paracetamol enterally
11. Patients who received paracetamol intravenously
12. Patients stratified by tertiles of APACHE II scores
Finally, to further decrease the impact of early
deaths as well as early discharges, and as an additional
sensitivity analysis, we used a cutoff time point of
20 hours when approximately two-thirds of patients
had received exposure to paracetamol and close to
40% of patients had either died or been discharged.
These patients were excluded from analysis. This cutoff
point was selected without knowledge of patient outcomes
and was based on the frequency distribution of paraceta-
mol exposure.
In this cohort, for the purpose of sensitivity analysis, we
retested the Cox proportional hazards model with paraceta-
mol treatment as a time-dependent variable adjusting
for hospital, diagnosis, APACHE III score, presence of
treatment limitations orders, surgical admissions,
infection-related admission and propensity to receive




We screened 17,110 patients. We excluded 1,292
patients (missing diagnosis in 71; missing APACHE
III score in 203, missing temperature in 19 and miss-
ing outcome in 972) and thus studied a total of
15,818 patients. Of these 10,046 patients (63.5%)
were given at least 1 g of paracetamol with more
than 90% of patients having their first exposure to
paracetamol within the first 48 hours of ICU admission
(Additional file 1: Figure E1).
The baseline characteristics, physiological data and
outcomes for patients who did or did not receive
paracetamol are shown in Table 1. As expected, there
were significant imbalances between groups. In par-
ticular, patients who received paracetamol were more
likely to be post-operative admissions, had higher
maximum temperature values and were more likely to
have fever. Among study patients, 4,397 (27.8%) had
at least one episode of temperature >38.0°C during
their ICU stay. An infection-related admission diagno-
sis was present in a similar percentage of patients in
both groups.
Table 1 Comparison of the characteristics of patients who received or did not receive at least one dose of
paracetamola
All patients, N =15,818 No paracetamol, n =5,772 Paracetamol, n =10,046 P-value
Age, yr 64 (51 to 73) 62 (49 to 73) 64 (52 to 73) <0.001
Male sex 64% (1,019) 63% (3,631) 65% (6,568) 0.002
APACHE II score 16.9 (7.18) 17.7 (8.4) 16.5 (6.3) <0.001
SAPS II score 29.5 (22.4) 28.3 (26.2) 30.2 (19.8) <0.001
Hospital A 20.3% (3,206) 14% (786) 24% (2,419) <0.001
Hospital B 10.9% (1,718) 11% (631) 11% (1,087) 0.83
Hospital C 10.2% (1,607) 12% (707) 9% (900) <0.001
Hospital D 58.7% (9,288) 63% (3,648) 56% (5,640) <0.001
Mechanical ventilationb 73% (11,513) 70% (4,032) 74% (7,481) <0.001
Acute renal failurec 6% (944) 8% (477) 5% (457) <0.001
Surgical admissionsd 63% (9,994) 51% (2,949) 70% (7,045) <0.001
Elective surgery 49% (7,707) 37% (2,154) 55% (5,553) <0.001
Infection as admission diagnosise 9% (1,419) 9% (518) 9% (901) 0.99
Number of temperature measurements 15 (9 to 36) 11 (5 to 20) 18 (11 to 49) <0.001
Mean temperature, °C 36.7 (0.7) 36.6 (0.8) 36.8 (0.6) <0.001
Highest temperature, °C 37.6 (1.0) 37.4 (0.9) 37.8 (1.0) <0.001
Lowest temperature, °C 35.4 (2.2) 35.6 (1.9) 35.4 (2.4) <0.001
SD of temperature, °C 0.62 (0.46) 0.59 (0.50) 0.64 (0.43) <0.001
Temperature >38°Cf 28% (4,397) 18% (984) 34% (3,413) <0.001
Temperature >38.3°Cf 20.3% (3,212) 11% (647) 26% (2,565) <0.001
Temperature >38.5°Cf 15.5% (2,456) 7% (429) 20% (2,027) <0.001
Temperature >39°Cf 7.9% (1,247) 3% (174) 11% (1,073) <0.001
Temperature <35°Cf 37.6% (5,949) 33% (1,927) 40% (4,022) <0.001
Total dose, g 1 (0 to 4) 0 (0 to 0) 3 (2 to 7) <0.001
Mean daily dose,g g 1 (0 to 2) 0 (0 to 0) 1.9 (1.0 to 2.6) <0.001
aAPACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; SD, Standard deviation. bMechanical ventilation within first
24 hours of ICU admission. c24-hour urine output is <410 ml AND creatinine >133 μmol/L AND patient is not receiving chronic dialysis. dAPACHE III-J principal
postoperative diagnosis. eA list of admission diagnosis with infection is provided in Additional file 1. fIndicates the presence of a given temperature at any time
during intensive care unit stay. gMean daily dose calculated by dividing total dose by number by treatment days.
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Overall, 2,164 patients (14%) died during hospitalization
(Table 2). Survivors had a lower maximum temperature,
were less likely to have a temperature >38.0°C and were
also more likely to receive paracetamol (Table 2).
Administration of paracetamol was associated with an
unadjusted reduction of in-hospital mortality (996 (9.9%)
vs. 1,168 (20.1%) deaths; P <0.0001) and ICU mortality
(530 (5.3%) vs. 858 (14.9%) deaths; P <0.0001). The
Kaplan-Meier survival plot for all study patients is
shown in Figure 1.
In multivariate logistic regression analysis, administra-
tion of paracetamol was significantly and independently
associated with reduced in-hospital mortality (adjusted
OR =0.60 (95% CI), 0.53 to 0.68), P <0.001) (Table 3). In
addition, Cox proportional hazards regression modeling
showed that patients who received paracetamol had asignificantly longer time to death (adjusted HR =0.51
(95% CI, 0.46 to 0.56), P <0.001) (Table 3).
Subgroup and sensitivity analysis
In surgical patients, administration of paracetamol
remained a significant predictor of better outcome
(Table 3, Figure 2a). Similar findings were observed in
medical patients, with increased survival in patients
treated with paracetamol (Table 3, Figure 2b). In addition,
paracetamol was significantly associated with better
outcomes in patients with and without fever (Table 3;
Figure 3a, b) and in patients with infection as the admission
diagnosis (Figure 4).
Importantly, however, in medical patients with fever
and infection as the admission diagnosis, after ad-
justment (including adjustment for propensity; see
Additional file 1: Tables E1 to E4 for details), paracetamol
Table 2 Baseline characteristics of the study patients according to survivala
Survivors, N =13,654 Dead, N =2,164 P-value
Age, yr 63 (50–73) 67 (55–76) <0.001
Male sex 65% (8827) 63% (1372) 0.26
APACHE II score 15.46 (5.78) 26.15 (8.13) <0.001
SAPS II score 26.9 (20.6) 45.5 (26.1)) <0.001
Hospital A 21% (2870) 15% (335) <0.001
Hospital B 11% (1474) 11% (244) 0.5
Hospital C 10%(1300) 14% (307) <0.001
Hospital D 59%(8010) 59% (1278) 0.73
Mechanical ventilationb 71% (9694) 84% (1819) <0.001
Acute renal failurec 71% (9694) 84% (1819) <0.001
Surgical admissionsd 4% (572) 17% (362) <0.001
Elective surgery 69% (9398) 28% (596) <0.001
Infection as admission diagnosise 55% (7507) 9% (200) <0.001
Number of temperature measurements 8% (1027) 18% (392) <0.001
Mean temperature, °C 36.7 (0.6) 36.6 (1.0) <0.001
Highest temperature, °C 37.6 (0.9) 37.9 (1.4) <0.001
Lowest temperature, °C 35.5 (2.1) 34.9 (2.6) <0.001
SD of temperature, °C 0.60 (0.45) 0.78 (0.49) <0.001
Temperature >38°Cf 26% (3469) 45% (928) <0.001
Temperature >38.3°Cf 18% (2441) 36% (771) <0.001
Temperature >38.5°Cf 13% (1812) 30% (644) <0.001
Temperature >39°Cf 6% (859) 18% (388) <0.001
Temperature <35°Cf 35% (4823) 52% (1126) <0.001
Number of patients given paracetamol 66% (9050) 46% (996) <0.001
Total dose, g 0 (0–0) 3 (2–7) <0.001
Mean daily dose,g g 0 (0–0) 1.9 (1.0-2.6) <0.001
aAPACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; SD, Standard deviation; bMechanical ventilation within first
24 hours of ICU admission; c24 hour urine output is <410 ml AND creatinine >133 μmol/L AND patient is not receiving chronic dialysis. dAPACHE III-J principal
postoperative diagnosis. eA list of admission diagnosis with infection is provided in Additional file 1. fIndicates the presence of a given temperature at any time
during intensive care unit stay. gMean daily dose calculated by dividing total dose by number by treatment days.
Figure 1 Kaplan-Meier survival plot for all patients according
to any exposure to paracetamol (yes) or no exposure to
paracetamol (no).
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(Table 3), but it was associated with prolonged time
to death.
When paracetamol was entered into the Cox propor-
tional hazards model as a time-dependent variable, the
independent association between paracetamol and
longer time to death diminished but remained significant,
except in the presence of fever or in patients with the
combination of medical admission, fever and infection,
where it failed to reach the predetermined significance
level of P <0.01 (Table 4). Moreover, when the model was
repeated after excluding early deaths and discharges
(<20 hours) and with paracetamol at a time-dependent
variable and fever also as a time-dependent variable,
the findings did not materially change (Additional file 1:
Table E5). We also adjusted the above prediction model
for other potential confounders. These included cirrhosis
Table 3 Adjusted odds ratios and hazards ratios for in-hospital mortality with the binary factor of paracetamol
administrationa
N Adjusted OR (95% CI) P-value Adjusted HR (95% CI) P-value
Allb 15,818 0.60 (0.53 to 0.68) <0.001 0.51 (0.46 to 0.56) <0.0001
Surgeryc
Yes 9,994 0.72 (0.58 to 0.91) 0.006 0.51 (0.42 to 0.61) <0.0001
No 5,824 0.56 (0.48 to 0.66) <0.001 0.51 (0.45 to 0.57) <0.0001
Feverd
Yes 4,397 0.76 (0.61 to 0.93) 0.009 0.57 (0.49 to 0.66) <0.0001
No 11,421 0.54 (0.46 to 0.64) <0.001 0.49 (0.43 to 0.56) <0.0001
Medical, fever and infectione 681 0.67 (0.42 to 1.05) 0.08 0.47 (0.33 to 0.65) <0.0001
aCI, Confidence interval; HR, Hazard ratio; OR, Odds ratio. bAdjusted for Acute Physiology and Chronic Health Evaluation (APACHE) II score, hospital, surgical
patient, infection as admission diagnosis, presence of fever, APACHE III admission diagnosis group, treatment limitation and propensity score (for receiving
paracetamol). cAdjusted for APACHE II score, hospital, infection as admission diagnosis, presence of fever, APACHE III admission diagnosis group, treatment
limitation and propensity score (for receiving paracetamol). dAdjusted for APACHE II score, hospital, surgical patient, infection as admission diagnosis, APACHE III
admission diagnosis group, treatment limitation and propensity score (for receiving paracetamol). eAdjusted for APACHE II score, hospital, APACHE III admission
diagnosis group, treatment limitation and propensity score (for receiving paracetamol).
Figure 2 Kaplan-Meier survival plots. (a) Plot for surgical patients
according to any exposure to paracetamol (yes) or no exposure to
paracetamol (no). (b) Plot for medical patients according to any
exposure to paracetamol (yes) or no exposure to paracetamol (no).
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intravenous vs. enteral paracetamol, the presence of differ-
ent temperature levels and tertiles of APACHE II scores.
These additional analyses identified that the association
between paracetamol and decreased mortality lost signifi-
cance after adjustment for temperature >38.3°C, >38.5°C
or >39°C and after adjustment for the lowest two tertiles
of APACHE II scores (Additional file 1: Table E6).
Discussion
Key findings
We conducted a multicenter, retrospective, observational
study in a large cohort of patients admitted to four ICUs
to examine the relationship between the use of paraceta-
mol and patient outcome. We found a significant and
independent association between the use of paracetamol
and reduced in-hospital mortality. Additionally, the asso-
ciation between paracetamol and mortality was broadly
consistent across subgroups. However, the strength of
this association was attenuated, both in patients with
fever in general and, particularly when paracetamol was
treated as a time-dependent variable, in patients with a
temperature >38.3°C, in medical patients with fever and
an infection-related admission diagnosis and in patients
in the lower tertiles of APACHE II score. In addition,
the association may have been affected by indication
bias, despite multiple other adjustments.
Relationship with previous studies
Researchers in a few previous studies have described the
use of antipyretic therapy to treat fever in ICU patients.
In studies done in North America [15], Australia [17]
and New Zealand [6], acetaminophen (paracetamol) was
given to 58% to 70% of ICU patients. In our study,
consistent with previous reports, 64% of patients admit-
ted to the ICU received paracetamol. This observation
Figure 4 Kaplan-Meier survival plot for medical patients with
an infection-related admission diagnosis and a fever according
to any exposure to paracetamol (yes) or no exposure to
paracetamol (no).
Table 4 Adjusted hazards ratio for in-hospital mortality
with paracetamol administration as a time-dependent
variablea
N Adjusted HR (95% CI) P-value
Allb 15,818 0.68 (0.61 to 0.75) <0.001
Surgeryc
Yes 9,994 0.64 (0.53 to 0.77) <0.001
No 5,824 0.72 (0.64 to 0.81) <0.001
Feverd
Yes 4,397 0.84 (0.72 to 0.98) 0.02
No 11,421 0.58 (0.50 to 0.66) <0.001
Medical, fever and infectione 681 0.70 (0.49 to 0.99) 0.04
aCI, Confidence interval; HR, Hazard ratio. bAdjusted for Acute Physiology and
Chronic Health Evaluation (APACHE) II score, hospital, surgical patient,
infection as admission diagnosis, presence of fever, APACHE III admission
diagnosis group, treatment limitation and propensity score (for receiving
paracetamol). cAdjusted for APACHE II score, hospital, infection as admission
diagnosis, presence of fever, APACHE III admission diagnosis group, treatment
limitation and propensity score (for receiving paracetamol). dAdjusted for
APACHE II score, hospital, surgical patient, infection as admission diagnosis,
APACHE III admission diagnosis group, treatment limitation and propensity
score (for receiving paracetamol). eAdjusted for APACHE II score, hospital,
APACHE III admission diagnosis group, treatment limitation and propensity
score (for receiving paracetamol).
Figure 3 Kaplan-Meier survival plots. (a) Plot for patients with
fever according to any exposure to paracetamol (yes) or no
exposure to paracetamol (no). (a) Plot for patients without fever
according to any exposure to paracetamol (yes) or no exposure
to paracetamol (no).
Suzuki et al. Critical Care  (2015) 19:162 Page 7 of 10confirms the fact that paracetamol is one of the most
common drugs prescribed in the ICU. However, such
practice may vary from country to country. For example,
a binational, prospective, observational study done in
Korea and Japan showed that only 148 (10%) of 1,425 ICU
patients admitted to the ICUs received any paracetamol
[12]. To our knowledge, no other studies have systematically
assessed paracetamol use in critically ill patients.
We found that paracetamol administration was inde-
pendently associated with reduced in-hospital mortality in
critically ill patients. This observation is not consistent
with two recently published meta-analyses whose authors
found antipyretic therapy was neither beneficial nor
harmful in critically ill adults without neurological injury
[15,18]. Since the publication of those meta-analyses,
investigators in a small randomized controlled trial have
assessed the impact of acetaminophen-based antipyretic
therapy strategies on the outcomes of critically ill patients
[3]. Although a preliminary pilot study, 28-day all-cause
mortality was not significantly different between theaggressive (2.6 g of paracetamol administered) and
permissive (no paracetamol) fever control group. More
recently, paracetamol was assessed in a small single-center
study in patients with sepsis and detectable plasma free
hemoglobin [19]. In that study of 40 patients, treatment
with paracetamol was associated with more favorable
biochemical outcomes: a decrease in F-isoprostanes and
serum creatinine in the first 2 to 3 days of treatment.
Thus, the effect of paracetamol administration for fever
control on patient-centered outcome in critically ill
patients remains unclear. A large (n =700) randomized
placebo-controlled trial investigating the safety and
Suzuki et al. Critical Care  (2015) 19:162 Page 8 of 10efficacy of paracetamol in febrile ICU patients with known
or suspected infection is currently underway [20,21].
Study implications
Our findings that paracetamol was associated with
decreased mortality in each subgroup, even after adjusting
for confounding factors, are of importance and are not in
keeping with our hypothesis. The use of paracetamol for
not only antipyretic but also analgesic effect is believed to
be common but has not been evaluated as an independent
risk factor for outcome in the ICU overall and in specific
ICU subgroups. Our findings that close to two-thirds of
our patients received paracetamol confirm that, at least in
the Australian and New Zealand context, paracetamol
prescription in the ICU is common. Our additional
findings that its administration is independently associated
with improved survival and that such association remains
after the use of propensity analysis, adjustments for key
outcome-predictive baseline variables, and consideration
of paracetamol administration as a time-dependent
variable all suggest the need to more formally evaluate the
role of paracetamol therapy in ICU patients. In addition,
the variability of this association when adjusted for
the degree of fever or illness severity or the presence
of suspected infection further invite assessment in
such specific groups.
Strengths and limitations
This study has several strengths. It involved more than
15,000 patients from 4 ICUs. This makes it the largest
study of the overall use of paracetamol in the ICU so far.
Moreover, by analyzing close to 700,000 temperature
measurements it allowed the most extensive assessment
of its use in association with fever in critically ill patients.
Finally, our study included a multifaceted statistical assess-
ment of the possible independent relationship between
the use of paracetamol and outcome using multiple
models and adjusting for illness severity and propensity to
receive paracetamol as well as the time-dependent nature
of its administration and the time-dependent impact
of fever, suspected infection and illness severity on its
prescription.
However, like other studies of associations based on
large databases, the present study is limited by the nature
of the data available. Thus, we are unable to comment on
interventions that might have affected body temperature,
such as renal replacement therapy or external cooling for
cardiac arrest. The study is also limited by the fact that no
causal inferences can be drawn from the observations re-
ported, especially because they may be markedly affected
by indication bias. Additionally, we were unable to deter-
mine whether paracetamol was given as an antipyretic or
as an analgesic or both. To attenuate the impact of this
limitation, we performed subgroup analysis to identifypatients more likely to receive paracetamol as either an
antipyretic (patients who had fever or infection or both)
or analgesic (patients after surgery) separately. We found
that even after we excluded surgical patients, to whom
paracetamol was most likely to have been given as an
analgesic medication, the association between paracetamol
and greater survival remained. As paracetamol is
commonly given to surgical patients for analgesia,
and as surgical patients have a better prognosis than
medical patients, paracetamol may have simply acted
as a marker of populations with an overall better
prognosis. However, we found that when medical patients
with fever and infection as the admission diagnosis (where
use of the drug as an analgesic seems unlikely) were ana-
lyzed separately, the association between paracetamol
therapy and increased survival time remained. Moreover,
its association with increased survival in such patients and
in patients with higher levels of fever or lower levels of ill-
ness severity, although losing significance, trended in a
similar direction up to a temperature of 39°C. It is possible
that paracetamol may have led to decreased use of
narcotics and that such narcotic sparing effects may
have been beneficial. Unfortunately, we do not have
information on the use of narcotics in our patients. It
is also possible that paracetamol may have led to decreased
use of non-steroidal anti-inflammatory drugs (NSAIDs)
and that such NSAID-sparing effects may have been
beneficial. Although we do not have information on
the use of NSAIDs in our patients, all units, by policy, use
such drugs very infrequently.
The opportunity to receive paracetamol in the ICU
varies with time and survival. Patients who are dis-
charged early from the ICU have less opportunity to
receive paracetamol and are also more likely to survive to
hospital discharge. This effect potentially makes it less
likely for paracetamol to be associated with better survival.
However, patients who die early in the ICU also have a
decreased probability of receiving paracetamol in the ICU,
thus influencing the association between paracetamol and
survival in a favorable direction. To compensate for such
confounders, we adjusted outcome models according to
the propensity to receive paracetamol and entered
paracetamol exposure as a time-dependent variable in
our statistical models. Such models continued to broadly
show a beneficial association between paracetamol admin-
istration and hospital survival. We then applied such
models after early discharges and early deaths were
removed. The findings were unaltered. We note, however,
that we were unable to develop a multilevel propensity
analysis based on exposure because specific dosages of
paracetamol were not available.
We defined fever as a temperature >38.0°C in accordance
with previous studies [17,18]. Although the Society of
Critical Care Medicine and the Infectious Diseases Society
Suzuki et al. Critical Care  (2015) 19:162 Page 9 of 10of America recommend that critically ill patients with a
temperature of at least 38.3°C be considered febrile [22],
evidence supporting such recommendations is lacking.
Indeed the definition of fever in the literature varies
widely, from at least 37.5°C to >39.0°C [22,23]. We
are unable to comment on site and mode of temperature
measurement. However, the measurement techniques
would have applied to patients receiving or not receiving
paracetamol in a similar way and seem unlikely to
have introduced bias. Of interest, however, only when
paracetamol was treated as a time-dependent variable
and fever was defined as a temperature >39°C was
the beneficial trend associating paracetamol with decreased
mortality reversed. It is in these febrile patients with
likely infection that paracetamol is currently being
tested against placebo in a multicenter phase IIb trial
(ACTRN12612000513819) [20,21].
Conclusions
Paracetamol administration was common in the study
ICUs and was independently associated with reduced
in-hospital mortality after adjustment for several
potential confounders. This association was broadly
consistent among various subgroups, such as surgical
or medical patients, but was attenuated in patients
with fever and in medical patients with an infection-
related admission diagnosis, in those with higher
levels of fever and in patients in the two lowest
tertiles of APACHE scores. Within the limitations of
a large, multicenter, observational study, our findings
suggest that paracetamol therapy may have an inde-
pendent relationship with patient outcome. Given
how commonly paracetamol is prescribed, and on the
basis of the evidence obtained in this study, a pro-
gram leading to randomized controlled trials designed
to investigate the impact of paracetamol administration
on patient outcomes in ICU appears both rational and
desirable.
Key messages
 Among critically ill patients, little is known about
the association between paracetamol administration
and patient outcomes.
 We conducted a large multicenter study and found
an independent association between paracetamol
administration and greater survival to hospital
discharge.
 This association applied to surgical and medical
patients and to febrile and non-febrile patients.
 This association remained present after Cox
proportional hazards analysis, propensity score
adjustment, treatment of paracetamol administration
as a time-varying variable and sensitivity analysis.Additional file
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